The global market size of vaginitis therapeutics was estimated at USD 2.9 billion in 2020 and is projected to reach USD 5.12 billion grow over the forecast period at a CAGR of 8.4 %. The awareness of women's health, the launch by key companies of new medicines and increasing demand for better healthcare services are some of the major driving factors for the sector.
Vaginitis is a frequently occurring medical disorder associated with substantial morbidity and complications that were previously undetected in women. Over the past few years, extensive research has led to the development of diagnostic tools as well as modalities for treating all forms of vaginitis. Vaginitis is a vaginal infection which can cause itching, discharge, and pain. The major forms of vaginitis include candida or "yeast" infections, bacterial vaginosis, tyrichomoniasis vaginitis, chlamydia vaginitis and viral vaginitis. About one third of women worldwide encounter symptoms of vaginitis at some point in their lives.
Many governmental and non-governmental organisations, such as the World Health Organization and the European Institute of Women's Health (EIWH), have taken steps to increase awareness of women's health problems. Continuous research and development efforts by various companies and growing women's lifestyle trend across the globe, such as smoking and alcohol consumption, are main drivers of market growth.
Leading players of this market are:
• Pfizer, Inc.;
• Merck & Co.
• Bayer AG;
• Lupin Pharmaceuticals, Inc.;
• Symbiomix Therapeutics, Inc. and
• Mission Pharmacal Company
• Abbott Laboratories,
• GlaxoSmithKline plc,
• Sanofi,
• Novartis AG
Most of these businesses are focusing on approaches such as partnerships, new product growth, M&A, expanding business in developing regions. Lupin Pharmaceuticals, for example, acquired Symbiomix Therapeutics in October 2017, to increase its product portfolio. As a strategic move, Pfizer Inc. announced in October 2017 that it will review the strategic option for spin off its Consumer Healthcare business.
Product-based demand for vaginitis therapeutics is segmented into drug-dependent anti-fungal, antibacterial, and hormone. The Anti-bacterial segment holds the biggest market share due to rising cases of bacterial vaginosis. The anti-bacterial market was projected on sales in 2017 at USD 900 million. An estimated 21 million people have suffered from this outbreak. Drugs used to treat the bacterial vaginosis, metronidazole, clindamycin and tinidazole.
It is classified as Over-The-Counter (OTC) and Prescription (Rx) by form on the basis of origin. Of these, the recommended form holds the largest market share due to improved effectiveness and protection against serious and persistent vaginitis. OTC is expected to grow at a CAGR of 8.7 percent over the forecast period, thanks to the presence of a wide variety of OTC products such as vaginal creams, gels and others.
Vaginitis is a frequently occurring medical disorder associated with substantial morbidity and complications that were previously undetected in women. Over the past few years, extensive research has led to the development of diagnostic tools as well as modalities for treating all forms of vaginitis. Vaginitis is a vaginal infection which can cause itching, discharge, and pain. The major forms of vaginitis include candida or "yeast" infections, bacterial vaginosis, tyrichomoniasis vaginitis, chlamydia vaginitis and viral vaginitis. About one third of women worldwide encounter symptoms of vaginitis at some point in their lives.
Many governmental and non-governmental organisations, such as the World Health Organization and the European Institute of Women's Health (EIWH), have taken steps to increase awareness of women's health problems. Continuous research and development efforts by various companies and growing women's lifestyle trend across the globe, such as smoking and alcohol consumption, are main drivers of market growth.
Leading players of this market are:
• Pfizer, Inc.;
• Merck & Co.
• Bayer AG;
• Lupin Pharmaceuticals, Inc.;
• Symbiomix Therapeutics, Inc. and
• Mission Pharmacal Company
• Abbott Laboratories,
• GlaxoSmithKline plc,
• Sanofi,
• Novartis AG
Most of these businesses are focusing on approaches such as partnerships, new product growth, M&A, expanding business in developing regions. Lupin Pharmaceuticals, for example, acquired Symbiomix Therapeutics in October 2017, to increase its product portfolio. As a strategic move, Pfizer Inc. announced in October 2017 that it will review the strategic option for spin off its Consumer Healthcare business.
Product-based demand for vaginitis therapeutics is segmented into drug-dependent anti-fungal, antibacterial, and hormone. The Anti-bacterial segment holds the biggest market share due to rising cases of bacterial vaginosis. The anti-bacterial market was projected on sales in 2017 at USD 900 million. An estimated 21 million people have suffered from this outbreak. Drugs used to treat the bacterial vaginosis, metronidazole, clindamycin and tinidazole.
It is classified as Over-The-Counter (OTC) and Prescription (Rx) by form on the basis of origin. Of these, the recommended form holds the largest market share due to improved effectiveness and protection against serious and persistent vaginitis. OTC is expected to grow at a CAGR of 8.7 percent over the forecast period, thanks to the presence of a wide variety of OTC products such as vaginal creams, gels and others.
- Aerospace and Defense
- Agriculture
- Automotive and Transportation
- Business and Finance
- Chemical and Materials
- Consumer Goods and Retails
- Electronics and Semiconductor
- Energy and Power
- Food and Beverages
- Machinery and Equipment
- Manufacturing and Construction
- Medical Devices
- Pharmaceuticals and Healthcare
- Service and Software
- Technology, Media and Telecommunications
- Travel and Tourism
